Single Drug Tear Sheet
$500
Peer Comparison Add-On
$750
HTA + Policy Calendar add-on
Contact Us for
Custom Pricing
custom scenario simulator
Contact Us for
Custom Pricing
live strategy briefing
Contact Us for
Custom Pricing
AI Assisted regulatory compliance SaaS
Join Our Waitlist
Have a portfolio, regulatory, or pricing question?
Submit your questionTrouble opening the form? Tap here to open it directly.
Sign up to receive the latest from AureusIQ — including new drug pricing reports, policy insights and early updates on the AI tools we're building.
Subscribe NowTrouble subscribing? Click here to open the form.
At AureusIQ, we are pioneering a new form of pharma intelligence. We marry AI-driven insights with human expertise to deliver real-time, actionable intelligence that empowers pharma companies, biotech startups, and institutional investors to make data-driven decisions faster and more efficiently.
Our approach is not just about technology and human collaboration—it’s a true partnership. The founding team behind AureusIQ is literally married, bringing together a unique blend of personal and professional synergy. This partnership mirrors the one we create between AI and human expertise, delivering insights that are both cutting-edge and deeply informed.
Traditional pharma consulting models can no longer keep up with the growing need for speed, clarity, and scalability in today’s rapidly changing healthcare landscape. That’s where AureusIQ steps in—providing the tools, insights, and expert guidance that help our clients thrive in times of disruption.
Why the name "AureusIQ"?
The name AureusIQ was inspired by the Latin word "Aureus", meaning "golden", signifying value that endures. It reflects the clarity, precision, and integrity we aim to deliver in an increasingly chaotic world we are living in, where these qualities are becoming rare. The “IQ” signifies not just intelligence, but Insight Quality—representing our signal over noise approach that ensures every piece of intelligence we provide is actionable, relevant, and of the highest quality you can trust. We are committed to delivering insights that you can depend on—providing the foundation for informed, confident decision-making in today’s complex and evolving market.
We offer a modern approach to pharma intelligence— one that is more responsive, smarter, and more flexible—so you can stay ahead of the curve.
Learn more about our vision for our future here.
Cloe Koh is a seasoned healthcare operator with a deep background in pharmacy and broad expertise in drug pricing, market access, and regulatory strategy across both public and private sectors. Trained as a pharmacist, she played a key role in national drug pricing benchmarking initiatives at Singapore’s Ministry of Health. At UnitedHealthcare/Optum, she led analytics efforts supporting senior leadership on Medicare Part B drug reimbursement strategy and financial risk—providing a data-driven lens into payer decision-making at scale.
As founder and CEO of AureusIQ, Cloe drives the development of MFN analytical products used by HEOR, market access, strategy teams, and healthcare investors to assess exposure to pricing regulation and policy-driven shifts across therapeutic categories. She is also spearheading the buildout of AI-powered tools that accelerate evidence synthesis and decision-making in complex regulatory environments. Her work sits at the intersection of policy, pricing, and data science—turning fragmented guidance into actionable insight. She brings a rare combination of clinical grounding, strategic clarity, and operational execution to one of healthcare’s most dynamic and high-stakes domains.
Dr. Mark Dranias is a computational neuroscientist and AI expert with over two decades of interdisciplinary experience spanning neuroscience, data science, computer vision, and large language models (LLMs). He brings deep academic and industry expertise to AureusIQ, driving the company’s AI strategy and end-to-end product architecture.
At AureusIQ, Dr. Dranias leads the development of AI agents that automate literature review, regulatory intelligence, and evidence synthesis by combining LLMs with structured data parsing. His work enables HEOR and market access teams to extract insights from vast, unstructured sources—including clinical literature, policy guidelines, and pricing databases—with speed and precision. He has built scalable, full-stack AI systems that integrate natural language processing, multimodal data analysis, and workflow automation to streamline decision-making across the healthcare value chain.
